Korean J Urogenit Tract Infect Inflamm.  2015 Apr;10(1):7-11. 10.14777/kjutii.2015.10.1.7.

Inflammation of Prostate and Prostate-Specific Antigen

• Cho IC
• Min SK

• KMID: 1839382
• DOI: http://doi.org/10.14777/kjutii.2015.10.1.7

Abstract

Noncancerous conditions (e.g., benign prostatic hyperplasia and prostatitis) can elevate serum prostate-specific antigen (PSA) levels, limiting the specificity of PSA screening for prostate cancer. In recent years, several studies have also demonstrated a relationship between chronic prostatitis/chronic pelvic pain syndrome and increased PSA levels. However, in asymptomatic patients, routine screening for this diagnosis is not performed before transrectal biopsy to rule out prostate cancer. These asymptomatic men with elevated PSA levels frequently show evidence of inflammation when their expressed prostatic secretions are examined, or on their prostate biopsy specimens. This raises the problem of appropriate evaluation in the presence of chronic prostatitis and elevated PSA levels not only in prostate cancer screening programs, but also in cancer-negative biopsy findings. Thus, there has been investigation into ways to decrease the confounding from inflammation, including repeat PSA measurements after a period of observation or a course of empiric antibiotics. This article reviews the evidence regarding elevations in PSA due to prostatitis and describes the controversy over the optimal approach to reduce its confounding impact on prostate cancer screening. Nowadays, it appears that in patients with prostatic inflammation and increased PSA, an antimicrobial regimen may provide more acceptable initial treatment than proceeding directly to prostate biopsy. Additional evidence is necessary in the form of a randomized clinical trial in which all patients undergo biopsy, regardless of the PSA response to antibiotic or placebo.

Keyword

Prostatitis; Prostate-specific antigen; Prostatic neoplasms

MeSH Terms

Anti-Bacterial Agents
Biopsy
Diagnosis
Humans
Inflammation*
Male
Mass Screening
Pelvic Pain
Prostate*
Prostate-Specific Antigen*
Prostatic Hyperplasia
Prostatic Neoplasms
Prostatitis
Sensitivity and Specificity
Anti-Bacterial Agents
Prostate-Specific Antigen

Reference

1. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003; 21:383–91.

2. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994; 151:1283–90.

3. Gilliland FD, Welsh DJ, Hoffman RM, Key CR. Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989-1993. Cancer Epidemiol Biomarkers Prev. 1995; 4:797–800.

4. Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995; 274:1445–9.

5. Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol. 1999; 161:529–33.

6. Roberts RO, Bergstralh EJ, Peterson NR, Bostwick DG, Lieber MM, Jacobsen SJ. Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997. J Urol. 2000; 163:1471–5.

7. Roberts RO, Bergstralh EJ, Lieber MM, Jacobsen SJ. Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997. Urology. 2000; 56:817–22.

8. Bahnson RR. Elevation of prostate specific antigen from bacillus Calmette-Guerin-induced granulomatous prostatitis. J Urol. 1991; 146:1368–9.

9. Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology. 1989; 33:465.

10. Neal DE Jr, Clejan S, Sarma D, Moon TD. Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate. 1992; 20:105–11.

11. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317:909–16.

12. Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, et al. Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol. 2011; 18:5875–83.

13. Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, et al. Prostate cancer screening facts, statistics and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol. 2012; 30:2581–4.

14. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ＜ or =4.0 ng per milliliter. N Engl J Med. 2004; 350:2239–46.

15. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006; 67:316–20.

16. Kwak C, Ku JH, Kim T, Park DW, Choi KY, Lee E, et al. Effect of subclinical prostatic inflammation on serum PSA levels in men with clinically undetectable prostate cancer. Urology. 2003; 62:854–9.

17. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995; 154:407–13.

18. Potts JM. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol. 2000; 164:1550–3.

19. Stancik I, Lüftenegger W, Klimpfinger M, Müller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol. 2004; 46:760–4.

20. Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol. 2002; 167:1723–6.

21. Schaeffer AJ, Wu SC, Tennenberg AM, Kahn JB. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol. 2005; 174:161–4.

22. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery–what we have learned and where we are going. J Urol. 1999; 162:293–306.

23. Kawakami J, Siemens DR, Nickel JC. Prostatitis and prostate cancer: implications for prostate cancer screening. Urology. 2004; 64:1075–80.

24. Brawn PN, Speights VO, Kuhl D, Riggs M, Spiekerman AM, McCord RG, et al. Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer. 1991; 68:1592–9.

25. Irani J, Levillain P, Goujon JM, Bon D, Doré B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol. 1997; 157:1301–3.

26. Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE Jr, Zeitlin S, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol. 2006; 176:119–24.

27. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol. 2000; 37:404–12.

28. Simardi LH, Tobias-MacHado M, Kappaz GT, Taschner Goldenstein P, Potts JM, Wroclawski ER. Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology. 2004; 64:1098–101.

29. Yaman O, Göğüş C, Tulunay O, Tokatli Z, Ozden E. Increased prostate-specific antigen in subclinical prostatitis: the role of aggressiveness and extension of inflammation. Urol Int. 2003; 71:160–4.

30. Kandirali E, Boran C, Serin E, Semercioz A, Metin A. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology. 2007; 70:743–7.

31. Matsubara A, Yasumoto H, Teishima J, Seki M, Mita K, Hasegawa Y, et al. Lower urinary tract symptoms and risk of prostate cancer in Japanese men. Int J Urol. 2006; 13:1098–102.

32. Oh JJ, Jeong SJ, Jeong CW, Byun SS, Hong SK, Choe G, et al. Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy-detectable prostate cancer in patients with PSA level below 20 ng/ml in multi-core prostate biopsy? Prostate. 2013; 73:42–7.

33. Faydaci G, Eryildirim B, Tarhan F, Goktas C, Tosun C, Kuyumcuoglu U. Does antibiotherapy prevent unnecessary prostate biopsies in patients with high PSA values? Actas Urol Esp. 2012; 36:234–8.

34. Serretta V, Catanese A, Daricello G, Liotta R, Allegro R, Martorana A, et al. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer Prostatic Dis. 2008; 11:148–52.